Symbicort Turbuhaler, 320+9 mcg/dose 60 doses

Pharmacotherapeutic group: bronchodilator combined (b2-adrenomimetic selective + local glucocorticosteroid)

ATX code: R03AK07

Pharmacological properties Pharmacodynamics

Simbicort^® Turbuhaler^® contains formoterol and budesonide, which have different mechanisms of action and have an additive effect in reducing the frequency of exacerbations of bronchial asthma and chronic obstructive pulmonary disease (COPD).

Budesonide. Budesonide is a glucocorticosteroid that has a rapid (within hours) and dose-dependent anti-inflammatory effect on the airways after inhalation, reducing the severity of symptoms and the frequency of exacerbations of bronchial asthma. When prescribing inhaled budesonide, there is a lower incidence of serious adverse effects than when using systemic glucocorticosteroids. It reduces the severity of bronchial mucosal edema, mucus production, sputum formation and airway hyperresponsiveness. The exact mechanism of anti-inflammatory action of glucocorticosteroids is unknown.

Formoterol. Formoterol is a selective b2-adrenergic receptor agonist that, after inhalation, causes rapid and prolonged relaxation of bronchial smooth muscle in patients with reversible airway obstruction. The bronchodilator effect is dose-dependent, occurs rapidly, within 1-3 minutes after inhalation and persists for at least 12 hours after a single dose.

Clinical efficacy and safety Bronchial asthma

The addition of formoterol to budesonide reduces the severity of bronchial asthma symptoms, improves bronchial function and reduces the frequency of exacerbations.

The action of Simbicort ^® Turbukhaler on bronchial function is similar to that of the combination of budesonide and formoterol monotherapies and greater than that of budesonide alone. In all cases short-acting beta2-adrenostimulator was used for seizure control. No decrease of antiasthmatic effect with time was noted. The drug has good tolerability.

Chronic Obstructive Pulmonary Disease (COPD)

In two studies lasting 12 months in patients with moderate to severe COPD (baseline: prebronchodilatation SPH1 < 50% of proper; median postbronchodilatation SPH1 = 42% of proper) on Symbicort^® Turbuhaler^® there was a significant reduction in the frequency of exacerbations compared with patients treated with formoterol or placebo alone (mean exacerbation rate of 1.4 compared with 1.8-1.9 in the placebo/formoterol group). No differences were noted between Symbicort^® and formoterol on first-second forced expiratory volume (FEF1).

Pharmacokinetics Intake

Symbicort^® Turbuhaler^® is bioequivalent to the respective monotherapies with respect to the systemic effects of budesonide and formoterol. Despite this, a slight increase in cortisol suppression was noted after administration of Symbicort^® Turbuhaler compared to the monotherapies. This difference has no effect on clinical safety. There is no evidence of pharmacokinetic interaction between budesonide and formoterol.

Pharmacokinetic parameters for the respective substances are comparable after administration of budesonide and formoterol as monotherapy and as part of Symbicort^® Turbuhaler^®. For budesonide, when administered as part of a combination drug, the area under the concentration-time curve (AUC) is slightly greater, the drug is absorbed faster and the value of the maximum plasma concentration is higher.

For formoterol when given as part of a combination drug, the maximum plasma concentration is the same as for the mono drug.

Inhaled budesonide is rapidly absorbed and reaches maximum plasma concentration 30 minutes after inhalation. The average dose of budesonide delivered to the lungs after inhalation via Turbuhaler^® is 32-44% of the delivered dose. Systemic bioavailability is approximately 49% of the delivered dose. In children aged 6 to 16 years, the average dose of budesonide delivered to the lungs after inhalation via Turbuhaler^® is not different from that in adult patients (final plasma concentration of the drug was not determined).

Inhaled formoterol is rapidly absorbed and reaches maximum plasma concentration 10 minutes after inhalation. The average dose of formoterol delivered to the lungs after inhalation via Turbuhaler^® is 28-49% of the delivered dose. Systemic bioavailability is approximately 61% of the delivered dose.

Distribution and metabolism

About 50% of formoterol and 90% of budesonide bind to plasma proteins. The volume of distribution for formoterol is about 4 l/kg and for budesonide 3 l/kg. Formoterol is inactivated by conjugation (active O-demethylated metabolites are formed, mostly as inactivated conjugates). Budesonide undergoes intensive biotransformation (about 90%) during the first passage through the liver to form metabolites with low glucocorticosteroid activity. Glucocorticosteroid activity of the main metabolites – 6-b-hydroxybudesonide and 16-a-hydroxyprednisolone – does not exceed 1% of similar activity of budesonide. There is no evidence of metabolite interaction or substitution reaction between budesonide and formoterol.

The bulk of the formoterol dose is metabolized in the liver and then excreted by the kidneys. After inhalation, 8-13% of the delivered dose of formoterol is excreted unchanged in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min); the half-life of the drug is on average 17 hours.

Budesonide is metabolized mainly with participation of CYP3A4 isoenzyme. Budesonide metabolites are excreted in the urine unchanged or as conjugates. Only small amounts of unchanged budesonide are detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min).

The pharmacokinetics of formoterol in children and patients with renal impairment have not been studied. Plasma concentrations of budesonide and formoterol may be elevated in patients with liver disease.

Indications

Bronchial asthma
Regular therapy of bronchial asthma in adults and adolescents 12-17 years of age in cases where it is advisable to use an inhaled glucocorticosteroid and a long-acting beta2-adrenergic agonist:
• in case of insufficient control of the disease using inhaled glucocorticosteroids and short-acting beta2-adrenergic agonists used “on demand”;
• with adequate disease control using inhaled glucocorticosteroids and long-acting beta2-adrenergic agonists.
Chronic obstructive pulmonary disease (COPD)
In adult patients over the age of 18 years, for symptomatic treatment of COPD with post-bronchodilator forced expiratory volume in the first second (FEV1) < 70% predicted and with a history of exacerbations, despite regular bronchodilator therapy.

Pharmacological effect

Pharmacotherapeutic group: combined bronchodilator (selective beta2-adrenergic agonist + local glucocorticosteroid)

ATX code: R03AK07

Mechanism of action and pharmacodynamic effects

Symbicort Turbuhaler contains formoterol and budesonide, which have different mechanisms of action and exhibit an additive effect in reducing the frequency of exacerbations of bronchial asthma and COPD.

Budesonide

Budesonide is a glucocorticosteroid that, after inhalation, has a rapid (within several hours) and dose-dependent anti-inflammatory effect on the airways, reducing the severity of symptoms and the frequency of exacerbations of bronchial asthma. When prescribing inhaled budesonide, there is a lower incidence of serious adverse effects than when using systemic glucocorticosteroids. Reduces the severity of edema of the bronchial mucosa, mucus production, sputum formation and airway hyperreactivity. The exact mechanism of the anti-inflammatory effect of glucocorticosteroids is unknown.

Formoterol

Formoterol is a selective beta2-adrenergic receptor agonist that, following inhalation, causes rapid and long-lasting relaxation of bronchial smooth muscle in patients with reversible airway obstruction. The bronchodilator effect is dose-dependent, occurs quickly, within 1-3 minutes after inhalation and persists for at least 12 hours after a single dose.

Clinical efficacy and safety

Bronchial asthma

The addition of formoterol to budesonide reduces the severity of symptoms of bronchial asthma, improves bronchial function and reduces the frequency of exacerbations of the disease.

The effect of the drug Symbicort Turbuhaler on bronchial function corresponds to the effect of the combination of budesonide and formoterol monotherapy and exceeds the effect of budesonide alone. In all cases, a short-acting beta2-agonist agonist was used to relieve attacks. There was no decrease in the anti-asthmatic effect over time. The drug is well tolerated.

COPD

In two 12-month studies in patients with moderate to severe COPD (baseline: pre-bronchodilator FEV1 < 50% predicted; median post-bronchodilator FEV1 = 42% predicted) with Symbicort Turbuhaler, a significant reduction in exacerbation rates was observed compared with patients receiving formoterol or placebo alone (median exacerbation rate 1.4 to compared to 1.8–1.9 in the placebo/formoterol group). There were no differences observed between the use of Symbicort and formoterol in FEV1.

Pharmacokinetic properties

Absorption

Symbicort Turbuhaler is bioequivalent to the corresponding monotherapy drugs in terms of the systemic action of budesonide and formoterol. Despite this, a slight increase in cortisol suppression was noted after the use of Symbicort Turbuhaler compared to monotherapy. This difference does not have an impact on clinical safety. There is no evidence of a pharmacokinetic interaction between budesonide and formoterol.

Pharmacokinetic parameters for the corresponding substances are comparable after the administration of budesonide and formoterol in the form of single drugs and as part of the drug Symbicort Turbuhaler. For budesonide, when administered as part of a combination drug, the area under the concentration-time curve (AUC) is slightly larger, the drug is absorbed faster and the maximum plasma concentration is higher.

For formoterol, when administered as part of a combination drug, the maximum concentration in blood plasma coincides with that for the single drug.

Inhaled budesonide is rapidly absorbed and reaches maximum plasma concentration 30 minutes after inhalation. The average dose of budesonide that enters the lungs after inhalation through Turbuhaler is 32-44% of the delivered dose. Systemic bioavailability is approximately 49% of the delivered dose. In children aged 6 to 16 years, the average dose of budesonide that enters the lungs after inhalation through Turbuhaler does not differ from those in adult patients (the final concentration of the drug in the blood plasma was not determined).

Inhaled formoterol is rapidly absorbed and reaches maximum plasma concentration 10 minutes after inhalation. The average dose of formoterol that enters the lungs after inhalation through Turbuhaler is 28-49% of the delivered dose. Systemic bioavailability is approximately 61% of the delivered dose.

Distribution and biotransformation

Approximately 50% of formoterol and 90% of budesonide are bound to plasma proteins. The volume of distribution for formoterol is about 4 l/kg and for budesonide 3 l/kg. Formoterol is inactivated by conjugation (active O-demethylated metabolites are formed, mainly in the form of inactivated conjugates). Budesonide undergoes intense biotransformation (about 90%) during the first passage through the liver with the formation of metabolites with low glucocorticosteroid activity. The glucocorticosteroid activity of the main metabolites – 6-b-hydroxybudesonide and 16-a-hydroxyprednisolone – does not exceed 1% of the similar activity of budesonide. There is no evidence of metabolite interactions or substitution reactions between budesonide and formoterol.

Elimination

The bulk of the dose of formoterol is metabolized in the liver and then excreted by the kidneys. After inhalation, 8-13% of the delivered dose of formoterol is excreted unchanged in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min); The half-life of the drug averages 17 hours.

Budesonide is metabolized primarily through the CYP3A4 isoenzyme. Budesonide metabolites are excreted in the urine unchanged or in the form of conjugates. Only a small amount of unchanged budesonide is found in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min).

The pharmacokinetics of formoterol in children and in patients with renal failure have not been studied. Plasma concentrations of budesonide and formoterol may be increased in patients with liver disease.

Special instructions

Impact on the ability to drive vehicles and operate machinery

Since visual disturbances have been reported in patients receiving this drug, patients should exercise caution before operating vehicles or machinery.

Active ingredient

Budesonide, Formoterol

Composition

Active ingredients: budesonide + formoterol.
Each delivered dose contains micronized budesonide 320 mcg and formoterol fumarate dihydrate 9 mcg.
Excipients, the presence of which must be taken into account in the composition of the medicinal product: lactose monohydrate – 491 mcg/dose.

Pregnancy

Pregnancy
There are no clinical data on the use of Symbicort or the simultaneous use of formoterol and budesonide during pregnancy. The results of an embryofetal toxicity study in rats did not reveal evidence of additional effects when the drugs were used in combination.

There is insufficient data on the use of formoterol in pregnant women. In animal studies, adverse events have been observed with very high doses of formoterol.
Data from approximately 2000 pregnancies associated with the use of the drug did not reveal an increased teratogenic risk associated with the use of inhaled budesonide. Glucocorticosteroids have been shown to cause birth defects in animal studies. However, this is probably not significant for patients receiving the drug at recommended doses.
Animal studies have also demonstrated the effects of excess prenatal glucocorticosteroids on increased risks of intrauterine growth restriction, cardiovascular disease in adulthood, and irreversible changes in glucocorticosteroid receptor density, neurotransmitter metabolism, and behavior when exposed to doses below teratogenic levels. During pregnancy, Symbicort should be used only in cases where the benefit of the drug outweighs the potential risk to the fetus. The lowest effective dose of budesonide needed to maintain adequate control of asthma symptoms should be used.

Lactation
Budesonide is excreted in breast milk, however, when used in therapeutic doses, no effect on the child was noted. It is not known whether formoterol passes into women’s breast milk. Formoterol was found in small amounts in the milk of lactating rats. Symbicort can be prescribed to breastfeeding women only if the expected benefit to the mother is greater than any possible risk to the baby.

Fertility
There are no data on the potential effects of budesonide on reproductive function. Animal reproductive studies with formoterol have shown a slight decrease in reproductive function in male rats with high systemic exposure.

Contraindications

Hypersensitivity to budesonide, formoterol or any of the excipients+.
Children’s age up to 12 years.
Lactose intolerance, lactase deficiency or glucose-galactose malabsorption.*

Special instructions and precautions for use

With caution: pulmonary tuberculosis (active or inactive form), fungal, viral or bacterial infections of the respiratory system, thyrotoxicosis, pheochromocytoma, diabetes mellitus, decreased function of the adrenal cortex, uncontrolled hypokalemia, hypertrophic obstructive cardiomyopathy, idiopathic hypertrophic subaortic stenosis, severe arterial hypertension, aneurysm of any location or other severe cardiovascular diseases (coronary heart disease, tachyarrhythmia or severe heart failure), prolongation of the QT interval (the use of formoterol may cause prolongation of the QTc interval), pregnancy, breastfeeding.

Dosage Directions

Patients are advised to carry emergency medications (short-acting beta2-agonists) with them at all times.

The patient’s attention should be drawn to the need for regular use of the drug Symbicort Turbuhaler in accordance with the selected dose, even in cases where there are no symptoms of the disease.

It is recommended to instruct the patient on the need to rinse the mouth with water after inhalation in order to prevent the development of candidiasis of the oral mucosa and pharynx.

It is recommended to gradually reduce the maintenance dose of the drug before stopping treatment and it is not recommended to abruptly discontinue treatment. Inhaled glucocorticosteroids should not be completely discontinued, except in cases where temporary withdrawal is necessary to confirm the diagnosis of bronchial asthma.

The drug Symbicort Turbuhaler is not intended for the initial selection of therapy in the first stages of treatment of bronchial asthma.

Increased symptoms of the disease

If therapy is insufficiently effective or recommended doses are exceeded, it is necessary to reconsider treatment tactics. Sudden and progressive deterioration in control of symptoms of asthma or COPD is a potentially life-threatening condition and requires urgent medical attention. In this situation, you should consider increasing the dose of glucocorticosteroids or adding systemic anti-inflammatory therapy, for example, a course of oral glucocorticosteroids or antibiotic treatment in case of infection. In case of severe exacerbation, therapy only with the use of a combination of an inhaled glucocorticosteroid and a long-acting beta2-adrenergic agonist is not enough.

Transfer from oral therapy

If there is reason to believe that adrenal function has been impaired due to previous systemic glucocorticosteroid therapy, precautions should be taken when transferring patients to treatment with Symbicort Turbuhaler. The benefits of inhaled budesonide therapy generally minimize the need for oral steroids, but patients who discontinue oral corticosteroid therapy may experience long-term adrenal insufficiency. Patients who have previously required acute high-dose corticosteroids or have received long-term treatment with high-dose inhaled corticosteroids may also be at risk. It is necessary to provide additional administration of glucocorticosteroids during periods of stress or surgery.

Excipients

Symbicort Turbuhaler contains lactose (< 1 mg/inhalation). Typically this amount does not cause problems in patients with lactose intolerance.

Interaction with other drugs

Concomitant use with itraconazole, ritonavir or other potent inhibitors of the cytochrome CYP3A4 isoenzyme should be avoided (see section 4.5). If this is not possible, the time interval between the use of interacting drugs should be as long as possible.

Precautions for specific diseases

Precautions should be taken when treating patients with a prolonged QTc interval. The use of formoterol may cause prolongation of the QTc interval.

The need for the use and dose of inhaled glucocorticosteroids should be reconsidered in patients with active or inactive forms of pulmonary tuberculosis, fungal, viral or bacterial infections of the respiratory system.

When beta2-agonists are co-administered with drugs that can cause or enhance the hypokalemic effect, for example, xanthine derivatives, steroids or diuretics, the hypokalemic effect of beta2-agonists may be enhanced. Special precautions should be taken in patients with unstable bronchial asthma who use short-acting bronchodilators to relieve attacks during exacerbation of severe bronchial asthma, since the risk of developing hypokalemia increases against the background of hypoxia and in other conditions when the likelihood of developing a hypokalemic effect increases. In such cases, it is recommended to monitor serum potassium levels.

During treatment, blood glucose concentrations should be monitored in patients with diabetes mellitus.

Systemic action

Systemic effects may occur when using any inhaled glucocorticosteroids, especially when using high doses of drugs over a long period of time. Systemic effects are less likely to occur with inhaled therapy than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataracts, and glaucoma.

Due to the potential effect of inhaled glucocorticosteroids on bone mineral density, special attention should be paid to patients using high doses of the drug for a long period with the presence of risk factors for osteoporosis. Studies of long-term use of inhaled budesonide in children at an average daily dose of 400 mcg (metered dose) or adults at a daily dose of 800 mcg (metered dose) did not show a significant effect on bone mineral density. There is no data regarding the effect of high doses of Symbicort Turbuhaler on bone mineral density.

Adrenal dysfunction

Treatment with systemic corticosteroids or inhaled budesonide should not be abruptly discontinued.

Long-term treatment with high doses of inhaled corticosteroids, especially those exceeding recommended doses, can also lead to clinically significant adrenal suppression. Therefore, additional systemic use of glucocorticosteroids should be considered during periods of stressful situations, such as severe infectious diseases or planned operations. A sharp reduction in the dose of glucocorticosteroids can cause an acute adrenal crisis. Symptoms and signs that may be observed in acute adrenal crisis can be quite vague, but may include anorexia, abdominal pain, weight loss, fatigue, headache, nausea, vomiting, decreased level of consciousness, seizures, hypotension and hypoglycemia.

Paradoxical bronchospasm

As with any other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. In this regard, you should stop therapy with Symbicort, reconsider treatment tactics and, if necessary, prescribe alternative therapy.

Pediatric patient population

It is recommended to regularly monitor the growth of children receiving long-term glucocorticosteroid therapy in inhaled form. In case of established growth retardation, therapy should be reconsidered in order to reduce the dose of inhaled glucocorticosteroid. It is necessary to carefully evaluate the ratio of the benefits of glucocorticosteroid therapy to the possible risk of growth retardation. When choosing therapy, it is recommended to consult a pediatric pulmonologist.

Based on limited data from studies of long-term corticosteroid use, it can be assumed that most children and adolescents treated with inhaled budesonide will eventually achieve normal adult height. However, minor (approximately 1 cm) short-term growth retardation has been reported, mainly in the first year of treatment.

Population of patients with COPD

Data from clinical studies of Symbicort Turbuhaler in patients with COPD with pre-bronchodilator FEV1 > 50% predicted and post-bronchodilator FEV1 < 70% predicted are not available.

Clinical studies and meta-analyses have shown that the use of inhaled corticosteroids during maintenance treatment of COPD may lead to an increased risk of pneumonia. Clinicians should be aware of the possibility of pneumonia in patients with COPD, since the clinical signs of pneumonia and exacerbation of the disease often overlap.

Side Effects

With the combined use of budesonide and formoterol, there was no increase in the incidence of adverse reactions. The most common adverse reactions associated with the use of the drug are such pharmacologically expected adverse reactions for beta2-adrenergic agonists, such as tremor and palpitations; symptoms are usually of moderate severity and resolve on their own within a few days after the start of treatment.

Adverse reactions associated with the use of budesonide or formoterol are listed below by organ system class and incidence. The frequency of reactions is presented in the following gradation: very often (≥1/10), often (≥1/100, but <1/10), infrequently (≥1/1000, but <1/100), rarely (≥1/10000, but <1/1000), very rarely (<1/10000).

Infections and infestations: often – candidiasis of the oral mucosa and pharynx, pneumonia (in patients with COPD).

Immune system disorders: rarely – immediate and delayed hypersensitivity reactions (for example, dermatitis, exanthema, urticaria, pruritus, angioedema and anaphylactic reaction).

Endocrine disorders: very rarely – Cushing’s syndrome, suppression of adrenal function, growth retardation, decreased bone mineral density.

Metabolic and nutritional disorders: rarely – hypokalemia; very rarely – hyperglycemia. Mental disorders: uncommon – aggressiveness, psychomotor agitation, anxiety, sleep disturbances; very rarely – depression, behavioral disorders (mainly in children).

Nervous system disorders: often – headache, tremor; infrequently – dizziness; very rarely – taste disturbances.

Violations of the organ of vision: infrequently – blurred vision; very rarely – cataract, glaucoma.

Cardiac disorders: often – palpitations; infrequently – tachycardia; rarely – arrhythmia (for example, atrial fibrillation, supraventricular tachycardia, extrasystole); very rarely – angina pectoris, prolongation of the QTc interval.

Vascular disorders: very rarely – fluctuations in blood pressure.

Disorders of the respiratory system, chest and mediastinal organs: often – cough, hoarseness, mild irritation of the pharyngeal mucosa; rarely – bronchospasm.

Gastrointestinal disorders: uncommon – nausea.

Skin and subcutaneous tissue disorders: uncommon – bruising.

Muscle, skeletal and connective tissue disorders: uncommon – muscle cramps.

Systemic effects of inhaled corticosteroids may occur when high doses are used over a long period of time.

The use of beta2-agonists can lead to an increase in the blood levels of insulin, free fatty acids, glycerol and ketone bodies.

Children

It is recommended to regularly monitor the growth of children receiving long-term treatment with inhaled glucocorticosteroids

Interaction

Pharmacokinetic interactions

Potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and human immunodeficiency virus (HIV) protease inhibitors) are likely to markedly increase budesonide plasma concentrations and concomitant use should be avoided. If this is not possible, the time interval between taking the inhibitor and budesonide should be as long as possible.

The potent CYP3A4 inhibitor ketoconazole, when administered at a dose of 200 mg once daily, increased the plasma concentration of budesonide during concomitant oral administration (single dose of 3 mg) by an average of 6 times. When ketoconazole was prescribed 12 hours after budesonide, the concentration increased on average only 3 times; this suggests that dividing the administration time may reduce the increase in plasma concentrations. Limited data on this interaction for high doses of inhaled budesonide indicate the possibility of a marked increase in plasma drug concentrations (on average 4-fold) when itraconazole 200 mg is used once daily with inhaled budesonide (single dose of 1000 mcg).

Pharmacodynamic interactions

Beta blockers may weaken or inhibit the effect of formoterol. Therefore, Symbicort should not be co-administered with beta-blockers (including eye drops) unless there is a compelling reason to do so.

Concomitant use of quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) and tricyclic antidepressants may prolong the QTc interval and increase the risk of ventricular arrhythmia.

In addition, levodopa, levothyroxine, oxytocin and alcohol can reduce the tolerance of the heart muscle to beta2-agonists.

Co-administration of monoamine oxidase inhibitors, as well as drugs with similar properties, such as furazolidone and procarbazine, may cause an increase in blood pressure.

There is an increased risk of developing arrhythmias in patients undergoing general anesthesia with halogenated hydrocarbon preparations.

Concomitant use of other beta-adrenergic or anticholinergic drugs may have potentially additive bronchodilatory effects.

Hypokalemia may increase the susceptibility to the development of arrhythmias in patients taking cardiac glycosides.

Hypokalemia may result from therapy with beta2-agonists and may be exacerbated by concomitant use of xanthine derivatives, glucocorticosteroids and diuretics.

There was no interaction between budesonide and formoterol with other drugs used to treat bronchial asthma.

Children

Drug interaction studies were conducted only in adult patients.

Overdose

Symptoms
Symptoms of formoterol overdose: tremor, headache, rapid heartbeat. In isolated cases, the development of tachycardia, hyperglycemia, hypokalemia, prolongation of the QTc interval, arrhythmia, nausea and vomiting was reported.
The use of formoterol at a dose of 90 mcg for 3 hours in patients with acute bronchial obstruction was safe.
In case of acute overdose of budesonide, even in significant doses, no clinically significant effects are expected. With chronic use of excessive doses, systemic effects of glucocorticosteroids, such as hypercortisolism and suppression of adrenal function, may occur.
If it is necessary to discontinue the drug Symbicort Turbuhaler due to an overdose of formoterol, which is part of the combination drug, the issue of prescribing an appropriate glucocorticosteroid should be considered.

Treatment
Supportive and symptomatic treatment may be prescribed.

Storage conditions

At temperatures below 30 C, in places inaccessible to children.

Shelf life

3 years. Do not use after expiration date.

Manufacturer

AstraZeneca AB, Sweden